XML 96 R91.htm IDEA: XBRL DOCUMENT v3.19.3
Agreement with Eli Lilly and Company - Other (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 02, 2018
USD ($)
item
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
item
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangements            
Equity investment $ 15,000     $ 31,000 $ 122,223 $ 25,000
Revenue   $ 1,583 $ 4,342      
Lilly Agreement            
Collaborative Arrangements            
Period of expiry from date of agreement 4 years          
Upfront non-refundable payment received $ 25,000          
Equity investment $ 15,000          
The number of performance obligations. | item 2   2      
Revenue   $ 1,600 $ 4,300   $ 0  
Lilly Agreement | Lilly            
Collaborative Arrangements            
Maximum development and regulatory milestones and sales milestone receivable $ 1,400,000          
Maximum development and regulatory milestones and sales milestone payable upon option exercise 710,000          
Transaction price $ 32,700